All documents in the Cochrane Database of Systematic Reviews are now in PDF format. That means no more tweaking the document to make sure that all the tables print and a document that is shorter in its final print version.
Other Cochrane News
"Two Cochrane Reviews to be published in January The Cochrane Library 2007,
Issue 1, report on smoking cessation:
• A recently licensed nicotine receptor stimulant trebles the odds of
stopping smoking. The new anti-smoking drug varenicline was first licensed for use in the UK on 5th December 2006. An early Cochrane Review of its effectiveness shows that it can
give a three-fold increase in the odds of a person quitting smoking. Varenicline is
the first new anti-smoking drug in the last ten years, and only the third, after NRT
and bupropion, to be licensed in the USA for smoking cessation.
• New evidence boosts the conclusion that some antidepressants can
double a smoker’s chance of quitting. The most recent Cochrane review concluded antidepressants bupropion (Zyban) and nortriptyline double a person’s chances of giving up smoking and have few side-effects, but selective serotonin reuptake inhibitors (SSRIs) such as
fluoxetine (Prozac) are not effective. A recently licensed nicotine receptor stimulant trebles the odds of stopping smoking. The new anti-smoking drug varenicline was first licensed for use in the UK on 5th December 2006. An early Cochrane Review' of its effectiveness shows that it can
give a three-fold increase in the odds of a person quitting smoking. Varenicline is the
first new anti-smoking drug in the last ten years, and only the third, after NRT and
bupropion, to be licensed in the USA for smoking cessation.
No comments:
Post a Comment